High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
作者： Ib Jarle Christensen , Nils Brünner , Keld Danø , Henning T. Mouridsen , Jan Grøndahl-Hansen
DOI:
关键词: Urokinase 、 Cancer research 、 Endocrinology 、 Plasminogen activator 、 Cancer 、 Epithelioma 、 Enzyme inhibitor 、 Mammary gland 、 Breast cancer 、 Internal medicine 、 Carcinoma 、 Medicine
摘要: Abstract The urokinase pathway of plasminogen activation is supposed to be involved in proteolytic degradation the extracellular matrix during cancer invasion. prognostic value urokinase-type activator (uPA) and type 1 inhibitor (PAI-1) levels cytosolic extracts ductal breast carcinomas was studied, retrospectively, 118 premenopausal 72 postmenopausal high-risk patients entered into protocol Danish Breast Cancer Cooperative Group trials for adjuvant treatment cancer. median observation time 8.5 years. uPA PAI-1 were determined by sandwich enzyme-linked immunosorbent assays. There a strong correlation between these (P
aacrjournals.org参考文章(32)
K. Danø, P.A. Andreasen, J. Grøndahl-Hansen, P. Kristensen, L.S. Nielsen, L. Skriver, Plasminogen activators, tissue degradation, and cancer. Advances in Cancer Research. ,vol. 44, pp. 139- 266 ,(1985) , 10.1016/S0065-230X(08)60028-7
Jari Pöllänen, Ross W. Stephens, Antti Vaheri, Directed Plasminogen Activation at the Surface of Normal and Malignant Cells Advances in Cancer Research. ,vol. 57, pp. 273- 328 ,(1991) , 10.1016/S0065-230X(08)61002-7
M.V. Cubellis, T.C. Wun, F. Blasi, Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. The EMBO Journal. ,vol. 9, pp. 1079- 1085 ,(1990) , 10.1002/J.1460-2075.1990.TB08213.X
F. Blasi, J. Eriksen, K. Danø, E. Ralfkiaer, P. Kristensen, C. Pyke, J. Grøndahl-Hansen, Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. American Journal of Pathology. ,vol. 138, pp. 1059- 1067 ,(1991)
M. B. Brown, Wilfrid Joseph Dixon, BMDP statistical software University of California Press. ,(1983)
Takeshi Oka, Toyohiko Nishino, Teruyoshi Ishida, Keizo Sugimachi, Immunohistochemical Evidence of Urokinase-type Plasminogen Activator in Primary and Metastatic Tumors of Pulmonary Adenocarcinoma Cancer Research. ,vol. 51, pp. 3522- 3525 ,(1991)
V Ellis, T C Wun, N Behrendt, E Rønne, K Danø, Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. Journal of Biological Chemistry. ,vol. 265, pp. 9904- 9908 ,(1990) , 10.1016/S0021-9258(19)38757-5
G Høyer-Hansen, E Rønne, H Solberg, N Behrendt, M Ploug, L.R. Lund, V Ellis, K Danø, Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. Journal of Biological Chemistry. ,vol. 267, pp. 18224- 18229 ,(1992) , 10.1016/S0021-9258(19)37176-5
L C Petersen, L R Lund, L S Nielsen, K Danø, L Skriver, One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. Journal of Biological Chemistry. ,vol. 263, pp. 11189- 11195 ,(1988) , 10.1016/S0021-9258(18)37940-7
Lund Lr, Danø K, Ralfkiaer E, Kristensen P, Kirkeby Lt, Grøndahl-Hansen J, Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. American Journal of Pathology. ,vol. 138, pp. 111- 117 ,(1991)